SOUTH SAN FRANCISCO, Calif. — March 2, 2026 — Leads & Copy — Cytokinetics, Incorporated (Nasdaq: CYTK) announced its management team’s participation in several investor conferences this month.
The conferences include:
- Leerink 2026 Global Healthcare Conference: A fireside chat is scheduled for Monday, March 9, 2026, at 9:20 AM Eastern Time in Miami Beach, FL.
- Citizens 2026 Life Sciences Conference: A fireside chat is scheduled for Tuesday, March 10, 2026, at 9:00 AM Eastern Time in Miami Beach, FL.
- 2026 Jefferies Biotech on the Beach Summit: One-on-one meetings will be held on Wednesday, March 11, 2026, in Miami Beach, FL.
- Barclays 28th Annual Global Healthcare Conference: A fireside chat is scheduled for Wednesday, March 11, 2026, at 2:30 PM Eastern Time in Miami Beach, FL.
Interested parties can access live webcasts of the fireside chats via the Investors & Media section of the Cytokinetics website.
Webcast replays will be archived on the website for 90 days following each event.
Cytokinetics is a cardiovascular biopharmaceutical company focused on muscle biology. Its product, MYQORZO™ (aficamten), is approved in the U.S., Europe, and China for treating adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is also being studied for non-obstructive HCM.
The company is also developing omecamtiv mecarbil, an investigational cardiac myosin activator, for heart failure with severely reduced ejection fraction, and ulacamten, an investigational cardiac myosin inhibitor, for heart failure with preserved ejection fraction.
Omecamtiv mecarbil and ulacamten are investigational medicines and have not been approved for any indication by regulatory agencies.
CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and other countries.
Source: Cytokinetics
